share_log

Senti Biosciences | 10-K: Annual report

Senti Biosciences | 10-K: Annual report

Senti Biosciences | 10-K：年度报表
美股sec公告 ·  03/21 22:21
Moomoo AI 已提取核心信息
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
临床阶段的生物技术公司Senti Biosciences报告称，截至2023年12月31日的年度净亏损为7,110万美元，而上一年的净亏损为5,820万美元。截至2023年12月31日，该公司的现金、现金等价物和短期投资总额为3590万美元，低于去年的9,860万美元。该年度的运营支出为9,530万美元，其中研发费用为3,220万美元。该公司确认将其阿拉米达工厂出售给GeneFab获得了2190万美元的收益，这也减少了长期运营支出。Senti Biosciences尚未从产品销售中获得收入，预计随着其基因回路平台技术和候选产品的临床开发，将继续出现巨额亏损和支出增加。该公司的未来计划包括专注于 SENTI-202 的临床开发，以及与Celest合作在中国的 SENTI-301A 项目。Senti Biosciences对在没有额外资金的情况下能否在未来十二个月之后继续作为持续经营企业表示担忧。
临床阶段的生物技术公司Senti Biosciences报告称，截至2023年12月31日的年度净亏损为7,110万美元，而上一年的净亏损为5,820万美元。截至2023年12月31日，该公司的现金、现金等价物和短期投资总额为3590万美元，低于去年的9,860万美元。该年度的运营支出为9,530万美元，其中研发费用为3,220万美元。该公司确认将其阿拉米达工厂出售给GeneFab获得了2190万美元的收益，这也减少了长期运营支出。Senti Biosciences尚未从产品销售中获得收入，预计随着其基因回路平台技术和候选产品的临床开发，将继续出现巨额亏损和支出增加。该公司的未来计划包括专注于 SENTI-202 的临床开发，以及与Celest合作在中国的 SENTI-301A 项目。Senti Biosciences对在没有额外资金的情况下能否在未来十二个月之后继续作为持续经营企业表示担忧。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息